Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Fröhner

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Deutsches Arzteblatt International|April 26, 2024
Certification Does not Necessarily Reduce MortalityMichael Fröhner
Aktuelle Urologie|January 13, 2004
[Prostatic carcinoma. Zoledronic acid raises bone density]Manfred Wirth, Michael Fröhner, Ralph Hausmann
Aktuelle Urologie|February 13, 2015
[Not Available]Michael Fröhner, Rainer Koch, Manfred Wirth
Urologia Internationalis|October 13, 2006
Treatment of locally advanced prostate cancer--the case for radical prostatectomyOliver W Hakenberg, Michael Fröhner, Manfred P Wirth
Urologia Internationalis|August 14, 2014
Superglue in the Urethra: Surgical TreatmentUlrike Heberling, Michael Fröhner, Sven Oehlschläger, et al.
Therapeutic Advances in Urology|July 27, 2011
Advances in renal cell carcinoma treatmentMarc-Oliver Grimm, Ingmar Wolff, Stefan Zastrow, et al.
Analytical and Quantitative Cytology and Histology|August 13, 2010
Correlation of centrosomal aberrations with cell differentiation and DNA ploidy in prostate cancerMarieta I Toma, Katrin Friedrich, Wolfdietrich Meyer, et al.
BMC Cancer|September 4, 2014
High serum levels of Dickkopf-1 are associated with a poor prognosis in prostate cancer patientsTilman D Rachner, Stefanie Thiele, Andy Göbel, et al.
Biomed Research International|May 31, 2014
Association of tissue mRNA and serum antigen levels of members of the urokinase-type plasminogen activator system with clinical and prognostic parameters in prostate cancerOmar Al-Janabi, Helge Taubert, Andrea Lohse-Fischer, et al.
Cancers|May 6, 2020
The Role of lncRNAs TAPIR-1 and -2 as Diagnostic Markers and Potential Therapeutic Targets in Prostate CancerMaik Friedrich, Karolin Wiedemann, Kristin Reiche, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Deutsches Arzteblatt International|April 26, 2024
Certification Does not Necessarily Reduce MortalityMichael Fröhner
Aktuelle Urologie|January 13, 2004
[Prostatic carcinoma. Zoledronic acid raises bone density]Manfred Wirth, Michael Fröhner, Ralph Hausmann
Aktuelle Urologie|February 13, 2015
[Not Available]Michael Fröhner, Rainer Koch, Manfred Wirth
Urologia Internationalis|October 13, 2006
Treatment of locally advanced prostate cancer--the case for radical prostatectomyOliver W Hakenberg, Michael Fröhner, Manfred P Wirth
Urologia Internationalis|August 14, 2014
Superglue in the Urethra: Surgical TreatmentUlrike Heberling, Michael Fröhner, Sven Oehlschläger, et al.
Therapeutic Advances in Urology|July 27, 2011
Advances in renal cell carcinoma treatmentMarc-Oliver Grimm, Ingmar Wolff, Stefan Zastrow, et al.
Analytical and Quantitative Cytology and Histology|August 13, 2010
Correlation of centrosomal aberrations with cell differentiation and DNA ploidy in prostate cancerMarieta I Toma, Katrin Friedrich, Wolfdietrich Meyer, et al.
BMC Cancer|September 4, 2014
High serum levels of Dickkopf-1 are associated with a poor prognosis in prostate cancer patientsTilman D Rachner, Stefanie Thiele, Andy Göbel, et al.
Biomed Research International|May 31, 2014
Association of tissue mRNA and serum antigen levels of members of the urokinase-type plasminogen activator system with clinical and prognostic parameters in prostate cancerOmar Al-Janabi, Helge Taubert, Andrea Lohse-Fischer, et al.
Cancers|May 6, 2020
The Role of lncRNAs TAPIR-1 and -2 as Diagnostic Markers and Potential Therapeutic Targets in Prostate CancerMaik Friedrich, Karolin Wiedemann, Kristin Reiche, et al.
Pageof 1